Press Releases

Date Title and Summary Additional Formats
Toggle Summary Harvard Bioscience, Inc. Invites You to Join its First Quarter 2001 Conference Call on the Web
Harvard Bioscience, Inc. Invites You to Join its First Quarter 2001 Conference Call on the Web HOLLISTON, Mass., April 19 /PRNewswire/ --Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce results for the first quarter of 2001 after the market closes on Wednesday, April 25, 2001. At 2:00 p.m.
View HTML
Toggle Summary Harvard Bioscience, Inc. to Continue Using Its Name
Harvard Bioscience, Inc. to Continue Using Its Name HOLLISTON, Mass., April 10 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today reported that the United States District Court, District of Massachusetts has denied Harvard University's request for a preliminary injunction prohibiting
View HTML
Toggle Summary Harvard Bioscience, Inc. President to Speak at Thomas Weisel Partners Healthcare Tailwinds Conference 2001
Harvard Bioscience, Inc. President to Speak at Thomas Weisel Partners Healthcare Tailwinds Conference 2001 HOLLISTON, Mass., March 28 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that David Green, President of Harvard Bioscience, will be a featured speaker at the Thomas
View HTML
Toggle Summary Harvard Bioscience, Inc. Launches New High Throughput Toxicity Screening Assays
Harvard Bioscience, Inc. Launches New High Throughput Toxicity Screening Assays HOLLISTON, Mass., March 19 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the introduction of MitoScan ® toxicity screening assays, which offer rapid, convenient alternatives to cellular assays.
View HTML
Toggle Summary Harvard Bioscience, Inc. Launches New ADMET Product
Harvard Bioscience, Inc. Launches New ADMET Product HOLLISTON, Mass., Feb. 27 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the introduction of ScanTox ™ , a drug safety evaluation tool that provides a more sensitive means of lead optimization than currently
View HTML
Toggle Summary Harvard Bioscience, Inc. Reports Financial Results For Fourth Quarter And Year Ended 2000
Harvard Bioscience, Inc. Reports Financial Results For Fourth Quarter And Year Ended 2000 HOLLISTON, Mass., Feb. 22 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today reported record revenues for the year and the quarter ended December 31, 2000.
View HTML
Toggle Summary Harvard Bioscience, Inc. Invites You to Join Its Fourth Quarter and Year Ended 2000 Conference Call on the Web
Harvard Bioscience, Inc. Invites You to Join Its Fourth Quarter and Year Ended 2000 Conference Call on the Web HOLLISTON, Mass., Feb. 14 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) You are invited to listen to our fourth quarter and year ended 2000 conference call.
View HTML
Toggle Summary Harvard Bioscience Announces Exercise of Overallotment
Harvard Bioscience Announces Exercise of Overallotment HOLLISTON, Mass., Jan. 9 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that the underwriters of its initial public offering have exercised in full their overallotment option to purchase an additional 937,500 shares.
View HTML
Toggle Summary Harvard Bioscience Completes Acquisition of Mitoscan Toxicology Testing Business
Harvard Bioscience Completes Acquisition of Mitoscan Toxicology Testing Business HOLLISTON, Mass., Dec. 28 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the acquisition of the high throughput toxicology screening business of Mitoscan Corporation of Madison, Wisconsin.
View HTML
Toggle Summary Harvard Apparatus Completes The Aquisition Of Amika Corporation
Harvard Apparatus Completes The Aquisition Of Amika Corporation Harvard Apparatus Inc. (HAI) of Holliston, MA, announced today that it has completed the acquisition of substantially all the assets of AmiKa Corp., whose products are at the heart of much of today's gene and protein discovery.
View HTML